There’s wide consensus that AI will shape the future of the profession. But there’s also uncertainty about what to do next, and even more so how to get there.
A limited federal tax credit, an above-the-line deduction for non-itemizers and restrictions on those of itemizers represent three of the biggest shifts under the new law.
Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval last year after an advisory committee was unable to verify a favorable risk/benefit profile.
Bloomberg Tax & Accounting released its annual report projecting U.S. tax rate brackets, standard deduction and AMT exemption amounts for the year ahead.